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We present a case report of a pediatric orthotopic liver 
transplant recipient who developed lymphoma with hy-
percalcemia on cyclosporine and prednisone immuno-
suppression. This is the first reported posttransplant 
lymphoproliferative disorder complicated by hypercal-
cemia, with a finding of an elevated 1,25 dihydroxyl 
vitamin D state, suggesting that it has a role in the 
pathophysiology of this B cell lymphoma hypercalcemia. 
The clinical course and management of this disorder 
with a 31-month follow-up are described. 
One unfortunate sequel of transplantation has been· post-
transplantation Epstein-Barr virus-mediated lymphoprolifer-
ative disease (1-3). It has been observed that these tumors are 
dissimilar from other lymphomas in that they are triggered by 
immunosuppression and may be reversible with discontinua-
tion or tapering of immunosuppressive agents (4). 
Hypercalcemia as a complication of pediatric lymphoma is 
uncommon and has an incidence of about 2.5%, as reported by. 
Le Blanc (5). A similar incidence of hypercalcemia complicat-
ing adult lymphomas, shown by Cancellos, was 1.8% (4/217) 
(6). The pathogenesis leading to malignancy-associated hyper-
calcemia has been inadequately elucidated, although a variety 
of mechanisms have been implicated, including direct bone 
1 Address reprint requests to Paul Nakazato, M.D., Transplant Serv-
ice, P.O. Box 7999, San Francisco, CA 94120. 
2 University of Pittsburgh School of Medicine. 
involvement, osteoclastic-activating factor, prostaglandins, 
parathyroid hormone, and vitamin D metabolites (7-11). 
We describe a pediatric orthotopic liver transplant recipient 
who developed lymphoma with hypercalcemia on cyclosporine 
and prednisone immunosuppression. 
MATERIALS AND METHODS 
In December 1983, a 211, year-old boy with biliary atresia cirrhosis, 
but no previous history of hypercalcemia, underwent orthotopic liver 
transplantation. Postoperatively, his course was uneventful and he was 
discharged with normal liver function tests and normal serum calcium 
(Fig. 1). 
At 27 months after transplantation, this patient was evaluated for 
abdominal pain consistent with acute appendicitis. Laparotomy re-
vealed a distal jejunoileal small bowel obstruction secondary to tumor, 
and right colectomy and enterocolostomy were performed. Pathology 
revealed a B celllymphoproliferative, monotypic IgM lambda-secreting 
tumor by routine hematoxylin-eosin and combined fluorescence and 
ABC-peroxidase techniques. Postoperatively, the patient's mainte-
nance immunosuppression was continued (Fig. 1). During this admis-
sion, the serum calcium and phosphorus remained normal. 
RESULTS 
At 28 months after transplantation, an abdominal comput-
erized axial tomography scan showed an abdominal tumor 
mass, approximately 8 em, located in the midabdomen. Immu-
nosuppression was altered by discontinuing cyclosporine but 
continuing prednisone (Fig. 1). 
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FIGURE 1. Immunosuppression and biochemical tests of a liver 
transplant recipient with lymphoproliferative disease. Note the nor-
malization of serum calcium following debulking of the tumor. Slight 
elevation of the hepatic enzymes followed discontinuation of daily 
At 291f2 months after transplantation, abdominal CAT scan 
continued to show a large mesenteric mass unchanged in size. 
A CAT scan-directed percutaneous needle biopsy and bone 
marrow aspirate showed recurrent lymphoproliferative B cell, 
monomorphic, and lambda light chain-producing tumor with-
out bone marrow involvement. Prednisone was discontinued 
and the patient was now totally off immunosuppressive agents. 
Calcium and phosphate serum levels were normal. 
At 31 months after transplantation, still totally off immu-
nosuppression, the patient was evaluated in our clinic and 
found to have hypercalcemia (15 mg/dI). Over the next several 
weeks, the patient was worked-up for his hypercalcemia. It was 
found by percutaneous liver biopsy and bone marrow aspirate 
that there was significant active cellular rejection in the liver 
transplant but no tumor present in the marrow. In the extensive 
hypercalcemia workup there were abnormal findings of an 
increased activity of serum angiotensin-converting enzyme, a 
normal 25-hydroxyl vitamin D level, and a markedly elevated 
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immunosuppression, consistent with mild rejection. (OL TX) ortho-
topic liver transplantation; (1) saline-Lasix therapy; (2) calcitonin 
therapy; (3) mithramycin therapy; (4) surgical debulking; and (5) 
surgical debulking. 
1,25 dihydroxy vitamin D (calcitriol) level. Management of 
hypercalcemia was difficult. Initially we attempted aggressive 
hydration and intravenous furosemide therapy but the hyper-
calcemia persisted. Persistent hypercalcemia refractory to cal-
citonin therapy (4 IV/kg subcutaneously), prompted a single 
dose of mithramycin (25 ILg/kg i.v.). Further usage of this 
medication was discarded because of hepatic toxicity. Finally, 
because the hypercalcemia was refractory to medical therapy 
with persistent abdominal pain and progressive lethargy, an 
exploratory laparotomy was performed, with mesenteric and 
omental tumor debulking and liver transplant biopsy. Pathol-
ogy again documented the same lymphoproliferative tumor, 
and the liver biopsy showed acute cellular rejection. At 9 days 
after operation, the patient was discharged with a calcium level 
of 12.5 mg/dl (Fig. 1), and without immunosuppression. Two 
weeks after debulking, the patient had normal serum calcium, 
phosphorus, 25-hydroxyl, and 1.25 dihydtoxy vitamin D levels. 
The patient's course after debulking was compounded by 
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problems of tumor recurrence. Partial small bowel obstruction 
prompted exploratory laparotomy and debulking at 38 months 
posttransplantation. Due to recurrence, chemotherapy trials 
consisting of cytoxan (40 mg/kg i.v.), vincristine (0.06 mg/kg 
Lv.), and prednisone (2.2 mg/kg p.o.) were attempted from the 
period of 43 months to 53 months posttransplantation. Carci-
nomatosis with partial small bowel obstruction occurred again, 
at 62 months after transplantation; this required laparotomy, 
small bowel resection, and further debulking. At that time, liver 
biopsy showed portal fibrosis, chronic inflammatory infiltrate 
in the portal triads, and intact bile ductules. Liver function 
tests were normal except for slightly elevated alkaline phos-
phatase. After the initial debulking at 31 months posttrans-
plantation, serum calcium and phosphorus levels were normal 
until the patient died 64 months after transplantation from 
mediastinal, pleural, and intraabdominal disease. 
DISCUSSION 
Our patient is unique for three reasons: this is the first 
reported case of posttransplantation lymphoproliferative dis-
order complicated by hypercalcemia; there is a possible corre-
lation between hypercalcemia and a lymphoproliferative tumor; 
associated with hypervitaminosis D; and the clinical course and 
management are unique. 
The literature on hypercalcemia and posttransplant lympho-
proliferative disease has revealed no previous report of this 
association. It is an uncommon complication even in the non-
transplant lymphoma population, with a 1.3%-4.0% occur-
rence. Our transplant experience in Pittsburgh shows an esti-
mated 1.6% incidence of posttransplant lymphoproliferative 
disorder-thus lymphoproliferative disease complicated by hy-
percalcemia occurs in 0.1 % of the total transplant population. 
In general, hypercalcemia and lymphomas usually become 
manifest with rampant disease-Le., osteolytic lesions and bone 
marrow metastases (13). In reviewing the literature, these 
lymphomas are usually T cell lymphomas rather than B cell 
lymphomas. In our case study, there was no evidence of any 
direct bone involvement, as suggested by a normal marrow, 
skeletal survey, and a bone scan. Our hypercalcemia workup 
excluded vitamin D, hypervitaminosis A, hyperthyroidism, 
parathyroid hormone-induced hypercalcemias, and sarcoidosis 
as causes of secondary hypercalcemia. 
De Remee and Banks (14) reported an association between 
non-Hodgkin's lymphoma hypercalcemia and an increased ac-
tivity of serum angiotensin -converting enzyme. Although our 
child did not have sarcoidosis, a similar association was found 
with an elevated serum angiotensin-converting eI}zyme, hyper-
calcemia, and abnormal vitamin D metabolism. At the time of 
the hypercalcemia, the patient had a normal 25-hydroxy vita-
min D level, which represents the precursor of the active 
metabolite 1,25 dihydroxy vitamin D (calcitriol); however, the 
latter was markedly elevated in our patient. 
Because the hypercalcitriol state did not appear to be gov-
erned by the usual physiologic mechanisms, and because de-
bulking the tumor caused normal calcemia and a precipitous 
decrease in the serum calcitriollevel, we believe that his B cell 
lymphoma had the capacity to maintain a hypercalcitriol state. 
By developing cell cultures from the tumor, we hope to inves-
tigate whether this B cell lymphoma has a capacity similar to 
the renal 25(OH) D3 I-alpha-hydroxylase enzyme to synthesize 
hypercalcitriol, or a role in controlling degradation. 
The clinical course was interesting. After detection and de-
bulking of the hypercalcemic lymphoproliferative disorder, the 
hypercalcemia and hypercalcitriol stage never recurred. Unfor-
tunately, the tumor never did regress with termination of 
maintenance immunosuppression, and even with chemotherapy 
treatment. Finally, 31 months after maintenance immuno-
suppression was terminated, the patient had not undergone 
fatal transplant rejection, but instead had a viable graft. It may 
be that the calcitriol levels present in our patient are com-
parable to results of in vitro experiments demonstrating the 
inhibitory effects of calcitriol on T helper cell proliferation 
(15). The possible interference of this with graft rejection may 
or may not be relevant, and further investigation will be re-
quired to determine whether calcitriol or sterol-like substances 
are causes of this phenomenon. 
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